Drugs / LGD-6972
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02672839 | Feb → May 2016 | type 2 diabetes mellitus | Ligand Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02250222 | Oct 2014 → May 2015 | type 2 diabetes mellitus | Ligand Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01919684 Comparator | Nov 2013 → Feb 2014 | type 2 diabetes mellitus | Ligand Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02851849 Comparator | Sep 2016 → Jun 2017 | type 2 diabetes mellitus | Ligand Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2017-09-05 | Ligand Pharmaceuticals | Results Ligand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes ligand.com ↗
LGD-6972 was safe and well tolerated, with no drug-related serious adverse events and no dose dependent changes in lipids (including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides), body weight or blood pressure after 12 weeks of treatment. |
| 2016-08-15 | Ligand Pharmaceuticals | Results Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism ligand.com ↗
The single- and multiple-dose Phase 1a and Phase 1b studies demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus. |
| 2015-06-07 | Ligand Pharmaceuticals | Results Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces results from a Phase 1b clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus. |
| 2014-11-18 | Ligand Pharmaceuticals | Results Ligand Provides Highlights from Today’s Analyst Day Event ligand.com ↗
At the Analyst Day event management profiled the product’s recent clinical data, which suggest significant market advantages for a safe, highly potent oral therapy compared with existing classes of new mechanisms. |
| 2014-06-16 | Ligand Pharmaceuticals | Results Ligand Announces Successful First-in-Human Trial Results for Glucagon Program ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. |
| 2013-10-07 | Ligand Pharmaceuticals | Regulatory Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antagonist Program ligand.com ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has opened an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and has obtained FDA approval to initiate clinical development for its Glucagon Receptor Antagonist program with LGD-6972 for the treatment of type 2 diabetes mellitus. |
| 2013-06-24 | Ligand Pharmaceuticals | Results Ligand Announces Positive Preclinical Data for Glucagon Program in Model of Type 1 Diabetes ligand.com ↗
The poster provides data from preclinical studies of Ligand’s novel compound, LGD-6972, demonstrating significant glucose lowering activity in an animal model of type 1 diabetes. |
| 2012-06-11 | Ligand Pharmaceuticals | Results Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association’s 72nd Scientific Sessions ligand.com ↗
LGD-6972 lowers glucose in a mouse model of type 2 diabetes mellitus |
All press releases naming this drug 11 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LGD-6972 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02851849 ↗ |
| Known as | MB-11262 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297469 ↗ |
| Modality | Small molecule | — CHEMBL4297469 ↗ |
| Route | Oral | “single oral dose” NCT01919684 ↗ |